Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
or

Crispr Therapeutics Ag (CRSP)

Crispr Therapeutics Ag (CRSP)
40.01 x 2 40.34 x 1
Pre-market by (Cboe BZX)
39.23 +1.41 (+3.73%) 04/22/25 [NASDAQ]
40.01 x 2 40.34 x 1
Pre-market 40.07 +0.84 (+2.14%) 05:17 ET
Quote Overview for Tue, Apr 22nd, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
38.34
Day High
39.85
Open 38.49
Previous Close 37.82 37.82
Volume 1,832,700 1,832,700
Avg Vol 2,467,655 2,467,655
Stochastic %K 81.61% 81.61%
Weighted Alpha -33.30 -33.30
5-Day Change +0.42 (+1.08%) +0.42 (+1.08%)
52-Week Range 30.04 - 67.88 30.04 - 67.88
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,266,249
  • Shares Outstanding, K 86,363
  • Annual Sales, $ 37,310 K
  • Annual Income, $ -366,250 K
  • EBIT $ -467 M
  • EBITDA $ -447 M
  • 60-Month Beta 1.85
  • Price/Sales 87.42
  • Price/Cash Flow N/A
  • Price/Book 1.67

Options Overview Details

View History
  • Implied Volatility 69.95% ( +0.12%)
  • Historical Volatility 69.28%
  • IV Percentile 94%
  • IV Rank 67.91%
  • IV High 81.49% on 04/08/25
  • IV Low 45.53% on 08/26/24
  • Put/Call Vol Ratio 0.15
  • Today's Volume 4,396
  • Volume Avg (30-Day) 7,804
  • Put/Call OI Ratio 0.59
  • Today's Open Interest 119,398
  • Open Int (30-Day) 102,662

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 28 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -1.27
  • Number of Estimates 10
  • High Estimate -0.74
  • Low Estimate -1.74
  • Prior Year -1.43
  • Growth Rate Est. (year over year) +11.19%

Price Performance

See More
Period Period Low Period High Performance
1-Month
30.04 +30.59%
on 04/07/25
Period Open: 41.22
42.72 -8.17%
on 03/24/25
-1.99 (-4.83%)
since 03/21/25
3-Month
30.04 +30.59%
on 04/07/25
Period Open: 44.20
55.88 -29.80%
on 02/19/25
-4.97 (-11.24%)
since 01/22/25
52-Week
30.04 +30.59%
on 04/07/25
Period Open: 55.66
67.88 -42.21%
on 06/13/24
-16.43 (-29.52%)
since 04/22/24

Most Recent Stories

More News
5 Monster Stocks -- Such as Coupang -- to Hold for the Next 10 Years

A "monster stock" might be one that frightens you by free-falling. Or it might alarm you with characteristics such as plummeting sales, shrinking profit margins, or surging debt. We'll use a different...

CRSP : 39.23 (+3.73%)
TTD : 48.66 (+2.31%)
CPNG : 21.68 (+2.60%)
AMZN : 173.18 (+3.50%)
PANW : 163.63 (+2.24%)
3 Magnificent Stocks That Could Double or More by 2030

When the stock market is as turbulent as it is these days, it's easy to forget the times when things are decidedly more cheery. However, sell-offs present great opportunities to buy stocks with significant...

VKTX : 25.48 (+7.42%)
CRSP : 39.23 (+3.73%)
SMMT : 27.35 (+8.45%)
Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals?

Vertex Pharmaceuticals (NASDAQ: VRTX) is a great example of biotech success. The company has built a cystic fibrosis (CF) empire, bringing in billions of dollars in revenue annually, and now is even expanding...

CRSP : 39.23 (+3.73%)
VRTX : 490.47 (+2.71%)
4 Beaten-Down Stocks That Could Skyrocket by 50% to 543%, According to Wall Street

As biotech investors know, companies in the industry can sometimes earn significant returns in relatively short periods, like a year, thanks to excellent clinical or regulatory progress. And based on Wall...

CRSP : 39.23 (+3.73%)
IOVA : 3.21 (+4.22%)
SRPT : 59.31 (+7.39%)
REGN : 585.49 (+4.27%)
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

The iconic growth investor made some interesting moves during Friday's market pullback.

BTC : 40.56 (+4.75%)
CRSP : 39.23 (+3.73%)
AMZN : 173.18 (+3.50%)
COIN : 190.00 (+8.57%)
Why Biotech Stocks Such as Biohaven, Recursion Pharmaceuticals, and CRISPR Therapeutics Plunged in March

Shares of early-stage biotech stocks, including Biohaven (NYSE: BHVN), Recursion Pharmaceuticals (NASDAQ: RXRX) , and CRISPR Therapeutics (NASDAQ: CRSP) , plunged in March, with the stocks down 35.3%,...

BHVN : 21.15 (+2.92%)
CRSP : 39.23 (+3.73%)
RXRX : 5.63 (+4.07%)
Why Biotech Stocks Like Recursion Pharmaceuticals, CRISPR Therapeutics, and Summit Therapeutics Plunged Today

Shares of biotechnology stocks such as Recursion Pharmaceuticals (NASDAQ: RXRX), Summit Therapeutics (NASDAQ: SMMT) , and CRISPR Therapeutics AG (NASDAQ: CRSP) plunged on Monday, down 9.4%, 5.6%, and 9.2%,...

CRSP : 39.23 (+3.73%)
SMMT : 27.35 (+8.45%)
RXRX : 5.63 (+4.07%)
2 Beaten-Down Stocks to Buy on the Dip

While the recent market dip has created bargains, some stocks have sufficiently lagged the market in the past year to warrant that title regardless of what's transpired in 2025. Among them are CRISPR Therapeutics...

CRSP : 39.23 (+3.73%)
MRK : 78.97 (+1.44%)
2 No-Brainer Biotech Stocks to Buy Right Now

Biotech is an area that may offer your portfolio growth today and earnings stability tomorrow. The idea is a biotech stock might soar as investors bet on the company's cutting-edge technology through its...

CRSP : 39.23 (+3.73%)
MRNA : 25.74 (+2.43%)
Prediction: CRISPR Therapeutics Will Beat the Market. Here's Why

Explore the exciting world of CRISPR Therapeutics (NASDAQ: CRSP) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends...

NVDA : 98.89 (+2.04%)
CRSP : 39.23 (+3.73%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

CRISPR Therapeutics AG is a leading gene editing company focused on developing CRISPR/Cas9-based therapeutics. The company is rapidly leveraging its CRISPR/Cas9 gene-editing platform to make therapies for the treatment of hemoglobinopathies, cancer, diabetes and other diseases.

See More

Key Turning Points

3rd Resistance Point 41.45
2nd Resistance Point 40.65
1st Resistance Point 39.94
Last Price 39.23
1st Support Level 38.43
2nd Support Level 37.63
3rd Support Level 36.92

See More

52-Week High 67.88
Fibonacci 61.8% 53.43
Fibonacci 50% 48.96
Fibonacci 38.2% 44.49
Last Price 39.23
52-Week Low 30.04

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Unlock High-Probability Trade Setups: Master Fractals & Time Frames Like a Pro